Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7722652 | 0.93 | FFAR1 (0.32) | DAOFFAR1 | |
| SCHEMBL7734812 | 0.92 | DAO (0.34) | DAOFFAR1KIF11 | |
| SCHEMBL7730606 | 0.91 | S1PR1 (0.35) | DAOTHRB | |
| SCHEMBL7722745 | 0.91 | DAO (0.36) | DAOFFAR1KIF11PTPN7DUSP3 | |
| SCHEMBL15317521 | 0.90 | DAO (0.33) | DAOFFAR1KIF11 | |
| SCHEMBL7728933 | 0.90 | KIF11 (0.41) | DAOFFAR1KIF11 | |
| SCHEMBL15744527 | 0.90 | DAO (0.32) | DAOPDK2 | |
| SCHEMBL7730346 | 0.89 | KIF11 (0.34) | DAOFFAR1KIF11 | |
| SCHEMBL7731510 | 0.89 | DAO (0.34) | DAOFFAR1KIF11PDK2CNR1 | |
| SCHEMBL14226611 | 0.89 | S1PR1 (0.34) | DAOTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846514-B2 | Liquid crystal compound, liquid crystal composition and, liquid crystal display device | CHISSO CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20100073621-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | CHISSO CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-0786445-B1 | DIFLUOROXYMETHANE DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | CHISSO CORP (JP) | 2002-07-17 | — | — | EP | disclosed |
| US-5858270-A | Difluorooxymethane derivative and liquid crystal composition | CHISSO CORPORATION (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0786445-A1 | DIFLUOROXYMETHANE DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100073621-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | TRPV4, TRPV5, ZKSCAN2 | DAO 3033/4885FFAR1 1394/4885KIF11 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.